leisure time -WSS

leisure time

author：focus 2025-09-30 22:10:39 - browse：5

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： How I ended up pumping milk in a bathroom stall at JPM 2024

explore

knowledge

WSS

Pfizer's Covid pill remains 89% effective in final analysis, company says

Can food be medicine? And other questions about a new push

Did the public have the right to know Arthur Ashe had AIDS?

Biotech reporter’s notebook: A sunnier mood at JPM 2024

4th of July breaks record for highest global temperature ever measured

Designating disabled people as health disparity population is crucial

Wikipedia

leisure time

Sign up for D.C. Diagnosis

explore

Sports medicine is finally prioritizing gender equality

Designating disabled people as health disparity population is crucial

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The nurse manager staffing crisis is hurting patients

Activists slam private health insurers over coverage restrictions

Grail is spending more than ever lobbying Congress

Virginia high school admissions case could be legal follow

Can food be medicine? And other questions about a new push

Moonlake's readout produced a cash windfall. Risks remain

As JPM 2024 winds down, some health tech firms project optimism

hotspot

When is a doctor not a doctor? Try when patients address women doctors

Grail is spending more than ever lobbying Congress

New menopause drug shows promise in relief for hot flashes

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Brain 'hot spot' may explain why African Americans feel greater pain

focus

explore

knowledge

focus